Kite Pharma Reports Results of Multi-Center Pivotal ZUMA-1 Trial of KTE-C19: 76% of Patients with Diffuse Large B-Cell Lymphoma Achieved Objective Response (p < 0.0001), 47% Complete Remissions at Pre-specified Interim Analysis